This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Jul;4(7):950-1.

doi: 10.18632/oncotarget.1029.

Asymmetric division: a marker for cancer stem cells in early stage tumors?

Pengcheng Bu, Kai-Yuan Chen, Steven M Lipkin, Xiling Shen

PMID: 23807730
PMCID: PMC3759670
DOI: 10.18632/oncotarget.1029

Editorial

Asymmetric division: a marker for cancer stem cells in early stage tumors?

Pengcheng Bu et al. Oncotarget. 2013 Jul.

. 2013 Jul;4(7):950-1.

doi: 10.18632/oncotarget.1029.

Authors

Pengcheng Bu, Kai-Yuan Chen, Steven M Lipkin, Xiling Shen

PMID: 23807730
PMCID: PMC3759670
DOI: 10.18632/oncotarget.1029

No abstract available

PubMed Disclaimer

Figures

Figure 1. Asymmetric division is associated with cancer stem cells in early-stage tumors
(Left) miR-34a regulates asymmetric division of cancer stem cells to form well-differentiated tumors in early-stage cancer. (Right) Late-stage cancer suppresses miR-34a and asymmetric division, which promotes symmetric self-renewal to form ∂undifferentiated tumors.

See this image and copyright information in PMC

Similar articles

Regulation of Asymmetric Cell Division in Mammalian Neural Stem and Cancer Precursor Cells.
Daynac M, Petritsch CK. Daynac M, et al. Results Probl Cell Differ. 2017;61:375-399. doi: 10.1007/978-3-319-53150-2_17. Results Probl Cell Differ. 2017. PMID: 28409314 Review.
Molecular Programs Underlying Asymmetric Stem Cell Division and Their Disruption in Malignancy.
Mukherjee S, Brat DJ. Mukherjee S, et al. Results Probl Cell Differ. 2017;61:401-421. doi: 10.1007/978-3-319-53150-2_18. Results Probl Cell Differ. 2017. PMID: 28409315 Review.
Asymmetric segregation and self-renewal of hematopoietic stem and progenitor cells with endocytic Ap2a2.
Ting SB, Deneault E, Hope K, Cellot S, Chagraoui J, Mayotte N, Dorn JF, Laverdure JP, Harvey M, Hawkins ED, Russell SM, Maddox PS, Iscove NN, Sauvageau G. Ting SB, et al. Blood. 2012 Mar 15;119(11):2510-22. doi: 10.1182/blood-2011-11-393272. Epub 2011 Dec 14. Blood. 2012. PMID: 22174158
The asymmetric division and tumorigenesis of stem cells.
Wang QZ, Lu YH, Jiang N, Diao Y, Xu RA. Wang QZ, et al. Chin J Cancer. 2010 Mar;29(3):248-53. doi: 10.5732/cjc.009.10668. Chin J Cancer. 2010. PMID: 20193105 Review.
New cancer diagnostics and therapeutics from a ninth 'hallmark of cancer': symmetric self-renewal by mutated distributed stem cells.
Sherley JL. Sherley JL. Expert Rev Mol Diagn. 2013 Nov;13(8):797-810. doi: 10.1586/14737159.2013.845087. Expert Rev Mol Diagn. 2013. PMID: 24151848 Review.

See all similar articles

Cited by

Transitional dynamics of cancer stem cells in invasion and metastasis.
Richard V, Kumar TRS, Pillai RM. Richard V, et al. Transl Oncol. 2021 Jan;14(1):100909. doi: 10.1016/j.tranon.2020.100909. Epub 2020 Oct 10. Transl Oncol. 2021. PMID: 33049522 Free PMC article. Review.
Cancer Stem Cells: From Historical Roots to a New Perspective.
Capp JP. Capp JP. J Oncol. 2019 Jun 11;2019:5189232. doi: 10.1155/2019/5189232. eCollection 2019. J Oncol. 2019. PMID: 31308849 Free PMC article. Review.
Murine melanoma cells incomplete reprogramming using non-viral vector.
Câmara DAD, Porcacchia AS, Costa AS, Azevedo RA, Kerkis I. Câmara DAD, et al. Cell Prolif. 2017 Aug;50(4):e12352. doi: 10.1111/cpr.12352. Epub 2017 Jun 15. Cell Prolif. 2017. PMID: 28618452 Free PMC article.
Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance.
Eid RA, Alaa Edeen M, Shedid EM, Kamal ASS, Warda MM, Mamdouh F, Khedr SA, Soltan MA, Jeon HW, Zaki MSA, Kim B. Eid RA, et al. Int J Mol Sci. 2023 Jan 16;24(2):1786. doi: 10.3390/ijms24021786. Int J Mol Sci. 2023. PMID: 36675306 Free PMC article. Review.
Juglone and KPT6566 Suppress the Tumorigenic Potential of CD44⁺CD133⁺ Tumor-Initiating Caco-2 Cells In Vitro and In Vivo.
Kim J, Lee S, Sun R, Kim J. Kim J, et al. Front Cell Dev Biol. 2022 Mar 30;10:861045. doi: 10.3389/fcell.2022.861045. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35433695 Free PMC article.

See all "Cited by" articles

References

1. Pece S, et al. Cell. 2010;140(1):62–73. - PubMed
1. Pine SR, et al. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(5):2195–2200. - PMC - PubMed
1. Dey-Guha I, et al. Proceedings of the National Academy of Sciences of the United States of America. 2011
1. Lathia JD, et al. Cell Death Dis. 2011;2:e200. - PMC - PubMed
1. O'Brien CA, et al. Cancer Cell. 2012;21(6):777–792. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

R01 GM095990/GM/NIGMS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations